Affordability and Value in Decision Rules for Cost-Effectiveness: A Survey of Health Economists.

ABSTRACT:

Objectives

New health technologies are often expensive, but may nevertheless meet standard thresholds for cost effectiveness, a situation exemplified by recent hepatitis C cures. Currently, cost-effectiveness analysis (CEA) does not supply practical means of weighing trade-offs between cost-effectiveness and affordability, particularly when costs and benefits are temporally separated and in health systems with multiple payers, such as the United States. We formally characterized disagreements in CEA theory and identified how these trade-offs are presently addressed in practice.

Methods

We surveyed 170 health economics researchers.

Results

When presented with a hypothetical cost-effective drug therapy in the United States that would require 20% of a state's Medicaid bu

SUBMITTER: Bilinski A 

PROVIDER: S-EPMC9342917 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature